10-K: Graphite Bio Navigates Strategic Shift, Discontinues Programs, and Pursues Merger with LENZ Therapeutics

Graphite Bio discontinues its gene editing programs, restructures operations, and enters into a merger agreement with LENZ Therapeutics, marking a significant strategic shift.

Summary

• Graphite Bio, a clinical-stage gene editing company, has discontinued its development programs, including its lead candidate nula-cel for sickle cell disease, following a serious adverse event in a clinical trial.
• The company underwent a corporate restructuring, resulting in a 78.1% reduction in workforce and the decision not to utilize a portion of its leased facilities.
• Graphite Bio entered into a license and option agreement with Kamau Therapeutics for its nula-cel program and an asset purchase agreement with Maro Bio for its non-genotoxic conditioning program.
• After a strategic review, Graphite Bio entered into a merger agreement with LENZ Therapeutics, with LENZ surviving as a wholly-owned subsidiary.
• The merger is subject to stockholder approval and other closing conditions, and if completed, LENZ's business will continue as the combined company's operations.
• The company's historical technology was based on CRISPR technology for targeted gene integration, with programs in gene correction, gene replacement, and targeted gene insertion.
• Graphite Bio has no commercial manufacturing capabilities and has relied on third-party contract manufacturing organizations.
• The company has in-licensed patents from Stanford University and Integrated DNA Technologies, Inc., which are subject to the license and option agreement with Kamau Therapeutics.

Sentiment

Score: 3

Explanation: The document reflects a significant strategic shift for the company, including the discontinuation of all development programs and a merger. While the merger could provide a path forward, the overall tone is negative due to the loss of the company's core business and the uncertainty surrounding the merger's success.

Positives

• The company has entered into a merger agreement with LENZ Therapeutics, which could provide a path forward for the company.
• Graphite Bio has secured a sublease for a portion of its facility, eliminating future rent obligations under the master lease.
• The company has retained key intellectual property and licenses related to its nula-cel program, subject to Kamaus option.
• The company has received an upfront payment of $0.5 million for the sale of its non-genotoxic conditioning technology.

Negatives

• Graphite Bio has discontinued all of its development programs, including its lead candidate nula-cel.
• The company has incurred significant losses since its inception and expects to continue to incur losses.
• The company has a limited operating history and has never generated revenue from product sales.
• The company is considered a shell company under federal securities laws due to the disposal of its assets.
• The company is subject to more stringent reporting requirements as a shell company.

Risks

• The merger with LENZ Therapeutics may not be completed, and the company may be required to pay a termination fee.
• The exchange ratio in the merger is based on net cash and not the market price of the company's common stock, which could result in a greater or lesser value than at the time the merger agreement was signed.
• The company may need to raise additional capital in the future, which could cause dilution to existing stockholders.
• The company's stock price may decline significantly if the merger is not completed.
• The company is subject to risks related to the development and commercialization of gene editing therapies, including regulatory hurdles and competition.
• The company's ability to use its net operating loss carryforwards may be limited.
• The company is dependent on its remaining employees to facilitate the consummation of the merger.
• The company's corporate restructuring may not result in anticipated savings and could disrupt its business.

Future Outlook

The company's future operations are highly dependent on the success of the merger with LENZ Therapeutics, and there is no assurance that the merger will be successfully consummated. If the strategic review process is unsuccessful, the board of directors may decide to pursue a dissolution and liquidation of the business.

Management Comments

• The merger was unanimously approved by our board of directors, and our board resolved to recommend approval of the Merger Agreement to our stockholders.
• Our future operations are highly dependent on the success of the merger and there can be no assurances that the merger will be successfully consummated.

Industry Context

The gene editing field is characterized by rapid technological change and significant competition. Several companies are advancing gene editing and gene therapy product candidates in preclinical or clinical development for similar indications, including Beam Therapeutics, bluebird bio, CRISPR Therapeutics, and Editas Medicine.

Comparison to Industry Standards

• Graphite Bio's decision to discontinue its lead program and pursue a merger is a significant departure from the typical trajectory of a clinical-stage biotech company.
• Companies like Beam Therapeutics, bluebird bio, and CRISPR Therapeutics are actively pursuing gene editing therapies for similar indications, but Graphite Bio's approach was unique in its focus on direct gene correction.
• The company's financial position, with significant losses and no product revenue, is not uncommon for early-stage biotech companies, but the strategic shift and merger plans are less typical.
• The company's reliance on third-party contract manufacturing organizations is standard practice in the biotech industry.

Management Changes

Legal Proceedings

• A complaint was filed by a purported stockholder against the company and its board of directors in connection with the proposed merger, alleging materially incomplete and misleading disclosures.
• The company has received four additional demands from purported stockholders seeking additional disclosures in the registration statement.

Related Party Transactions

• The company entered into a license and option agreement with Kamau Therapeutics, where Dr. Porteus, a director and stockholder of the company, is the founder and chief executive officer.
• The company sold its non-genotoxic conditioning technology assets to Maro Bio, which is formed by Samsara BioCapital and funds affiliated with Versant Ventures, both of which are greater than 5% stockholders of the company.

Stakeholder Impact

• Shareholders face significant uncertainty regarding the future of the company and the value of their investment.
• Employees have been significantly impacted by the workforce reductions and restructuring.
• Customers and partners may be affected by the discontinuation of the company's development programs.
• Creditors may be impacted by the company's financial losses and strategic shift.

Next Steps

• The company will seek stockholder approval for the merger with LENZ Therapeutics.
• The company will work to satisfy other closing conditions for the merger, including the effectiveness of a registration statement and Nasdaq approval.
• The company will continue to hold, maintain, and preserve the technology, licenses, and intellectual property related to its nula-cel program, subject to Kamaus option.
• The company will continue to evaluate strategic alternatives if the merger is not completed.

Key Dates

Keywords

gene editing, merger, LENZ Therapeutics, sickle cell disease, nula-cel, restructuring, intellectual property, clinical trials, biotechnology, CRISPR